P-Nitrophenol

P-Nitrophenol

SCHEMBL309332

O=C(O)O.O=[N+]([O-])c1ccc(O)cc1

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of P-Nitrophenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.61
CES1 P23141 2/20 0.58
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
CES2 O00748 1/20 0.55
SRD5A2 P31213 1/20 0.55
ALDH1A1 P00352 4/20 0.54
LMNA P02545 1/20 0.54
MAPK1 P28482 3/20 0.54
TSHR P16473 1/20 0.54
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ACHE P22303 1/20 0.50
HSD17B10 Q99714 1/20 0.50
POLB P06746 1/20 0.50
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Nitrophenol SCHEMBL14125735 1.00 TDP1 (0.61) TDP1CES1CA1CA2CES2
P-Nitrophenol SCHEMBL17289474 0.98 TDP1 (0.59) TDP1CES1CA1CA2CES2
P-Nitrophenol SCHEMBL27462973 0.95 TDP1 (0.60) TDP1CES1CA1CA2CES2
P-Nitrophenol SCHEMBL15203620 0.93 ALDH1A1 (0.64) TDP1CES1CA1CA2CES2
P-Nitrophenol SCHEMBL11048842 0.93 CES1 (0.58) TDP1CES1CA1CA2ALDH1A1
P-Nitrophenol SCHEMBL29806213 0.93 CES1 (0.58) TDP1CES1CA1CA2ALDH1A1
P-Nitrophenol SCHEMBL1839 0.93 CES1 (0.58) TDP1CES1CA1CA2ALDH1A1
P-Nitrophenol SCHEMBL5476151 0.92 TSHR (0.55) TDP1CES1CA1CA2CES2
P-Nitrophenol SCHEMBL64459 0.91 ALDH1A1 (0.61) TDP1CES1CA1CA2CES2
P-Nitrophenol SCHEMBL324522 0.91 TSHR (0.61) TDP1CES1CA1CA2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025128586-A1 TRACELESS LINKER AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-06-19 WO claimed
WO-2024222870-A1 ANTIBODY-DRUG CONJUGATE 石药集团巨石生物制药有限公司 2024-10-31 WO claimed
JP-4574007-B2 2010-11-04 JP claimed
EP-1421956-B1 Process for stepwise attachment of polyethylene glycol (PEG) to a polypeptide APPLIED RESEARCH SYSTEMS (AN) 2007-06-27 EP claimed
US-20070141620-A1 POLYOL-IFN-BETA CONJUGATE AND COMPOSITION CONTAINING SAME APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-06-21 US claimed
EP-1421956-A1 Process for stepwise attachment of polyethylene glycol (PEG) to a polypeptide Applied Research Systems ARS Holding N.V. (AN) 2004-05-26 EP claimed
US-20040043002-A1 Polyol-IFN-beta conjugate and composition containing same APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2004-03-04 US claimed
JP-2002512983-A 2002-05-08 JP claimed
EP-1075281-A2 POLYOL-IFN-BETA CONJUGATES Applied Research Systems ARS Holding N.V. (AN) 2001-02-14 EP claimed
WO-1999055377-A9 POLYOL-IFN-BETA CONJUGATES APPLIED RESEARCH SYSTEMS (NL) 2000-03-02 WO claimed
WO-1999055377-A2 POLYOL-IFN-BETA CONJUGATES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 1999-11-04 WO claimed
US-20260124317-A2 Antibody Drug Conjugates BEONE MEDICINES I GMBH (CH) 2026-05-07 US disclosed
WO-2025128586-A1 TRACELESS LINKER AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-06-19 WO disclosed
CN-120131677-A In-situ synthesis method of medicine and application thereof 北京大学 2025-06-13 CN disclosed
US-20250135026-A1 Antibody Drug Conjugates BEIGENE SWITZERLAND GMBH (CH) 2025-05-01 US disclosed
WO-1997033576-A1 CARBAMYL GUANIDINE AND AMIDINE PRODRUGS BRISTOL-MYERS SQUIBB COMPANY (US) 1997-09-18 WO disclosed
WO-1996029304-A1 NONPEPTIDES AS TACHYKININ ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1996-09-26 WO disclosed
EP-0730660-A1 CHIMERIC PROTEINS INCLUDING PROTEASE NEXIN-1 VARIANTS INCYTE PHARMACEUTICALS, INC. (US) 1996-09-11 EP disclosed
US-5554641-A Nonpeptides as tachykinin antagonists WARNER-LAMBERT COMPANY 1996-09-10 US disclosed
WO-1995011987-A1 CHIMERIC PROTEINS INCLUDING PROTEASE NEXIN-1 VARIANTS INCYTE PHARMACEUTICALS, INC. (US) 1995-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124317-A2 Antibody Drug Conjugates SLC3A2, SLC7A1, SLC43A1 TDP1 421/4885CES1 496/4885CA1 139/4885
US-20250135026-A1 Antibody Drug Conjugates CD22, FCGR2A, FCGR3B TDP1 3997/4885CES1 275/4885CA1 1067/4885
US-20040043002-A1 Polyol-IFN-beta conjugate and composition containing same IFNG, IFNAR1, IL2 TDP1 4231/4885CES1 3342/4885CA1 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.